Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-amyloid drugs

- PMLiVE

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes

- PMLiVE

FDA fast-tracks Jardiance for heart failure review

Would challenge Novartis' Entresto

Roche - Basel

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

First-in-class antibody drug conjugate

- PMLiVE

Lilly claims cluster headache first for CGRP drug Emgality

Competition fierce in new class

Roche Basel Switzerland

Roche/GE’s digital medicine alliance bears first fruit

While new player enters liquid biopsy market

Eli Lilly HQ

Latecomer Lilly preps its IL-23 drug for Crohn’s disease

Hopes to leapfrog rivals

- PMLiVE

Genentech forges $800m autoimmune alliance with Parvus

Big vote of confidence in novel platform

- PMLiVE

Roche and NHS England hail pricing deal on MS drug Ocrevus

Another pricing deal on high cost medicine

Eli Lilly HQ

Pricing pressures peg back Lilly’s growth products

Reduces its full year forecast as a result

Eli Lilly HQ

Lilly invests in antibody oligonucleotides conjugates with Avidity deal

Companies to develop new immonology medicines

Roche Basel Switzerland

Hemlibra off to a flyer as Roche raises 2019 forecasts

Drug has made almost as much in this quarter as it did in 2018

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links